Aiming Med, a leading provider of tumor precision medicine solutions based in Hangzhou, has announced a strategic partnership with Becton, Dickinson and Co. (BD) during the 6th China International Import Expo (CIIE) in Shanghai this week. This collaboration aims to enhance the application of advanced tumor organoid and single-cell multi-omics technologies.
The partnership will focus on leveraging BD’s cutting-edge capabilities in tumor organoid and single-cell sequencing techniques. By integrating these innovative technologies, Aiming Med and BD seek to revolutionize the landscape of precision medicine, providing more tailored treatment options for patients.
BD is renowned for its groundbreaking BD Rhapsody platform, the world’s first technology capable of simultaneously obtaining multiple omics data within a single experiment. This unique capability positions BD at the forefront of multi-omics research, making significant strides in the field of cancer treatment.
No financial details of the partnership were disclosed at this time, but the collaboration signifies a promising advancement in the realm of precision oncology.- Flcube.com
